Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in California: - AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- Mills-Peninsula Medical Center — Burlingame, California
- Palo Alto Medical Foundation-Fremont — Fremont, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in California: - Alta Bates Summit Medical Center Comprehensive Cancer Center — Berkeley, California
- John Muir Health Clinical Research Center — Concord, California
- UC San Diego Medical Center - Encinitas — Encinitas, California
- Providence Medical Foundation — Fullerton, California
- Providence St. Jude Medical Center — Fullerton, California
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in California: - Oncura Health - Anaheim — Anaheim, California
- Memorial Care Orange Coast Medical Center Attn — Fountain Valley, California
- MemorialCare Orange Coast Medical Center — Fountain Valley, California
- OC Blood and Cancer Care — Fountain Valley, California
- Oncura Health - Fountain Valley — Fountain Valley, California
Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Sites in California: - Providence Medical Foundation — Fullerton, California
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center — Fullerton, California
- Providence St. Jude Medical Center — Fullerton, California
- St. Jude Heritage Medical Group - Fullerton Plaza Multi-Specialty Clinic (Pulmonary Function Test) — Fullerton, California
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in California: - Research Site — Anaheim, California
- Research Site — Beverly Hills, California
- Research Site — Loma Linda, California
- Research Site — Los Alamitos, California
- Research Site — Redlands, California
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Cedars-Sinai Cancer - Tarzana — Tarzana, California
- Torrance Memorial Physician Network - Cancer Care — Torrance, California
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in California: - Research Site — Anaheim, California
- Research Site — Beverly Hills, California
- Research Site — Fountain Valley, California
- Research Site — Newport Beach, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in California: - Community Cancer Institute (CCI) — Clovis, California
- Marin Cancer Care Inc — Greenbrae, California
- UCI Health-CIACC — Irvine, California
- UCLA Oncology Center — Los Angeles, California
- Hoag Memorial Hospital — Newport Beach, California
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in California: - John Muir Clinical Research Center — Concord, California
- University Of California - San Diego Moores Cancer Center — La Jolla, California
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in California: - Providence St. Jude Medical Center ( Site 0106) — Fullerton, California
- VA Long Beach Healthcare System ( Site 0199) — Long Beach, California
- USC Norris Comprehensive Cancer Center ( Site 0205) — Los Angeles, California
- UCLA Jonsson Comprehensive Cancer Center ( Site 0135) — Los Angeles, California
- UCSF Medical Center at Mission Bay ( Site 0178) — San Francisco, California
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in California: - Providence Medical Foundation — Fullerton, California
- Local Institution - 0682 — Loma Linda, California
- Helios Clinical Research — Long Beach, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- Orange Coast Memorial Medical Center — Fountain Valley, California
- Local Institution - 0027 — Los Alamitos, California
- Local Institution - 0422 — Los Angeles, California
- Pacific Cancer Care — Monterey, California
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in California: - UCSD — La Jolla, California
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in California: - Research Site — La Mesa, California
- Research Site — Los Alamitos, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in California: - University of California San Diego — La Jolla, California
- UC Davis Comprehensive Cancer Center — Sacramento, California
Phase 3 Recruiting Industry
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT07365241
Sites in California: - City of Hope National Medical Center /ID# 281322 — Duarte, California
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 281396 — Irvine, California
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in California: - St. Jude Herritage Medical Group — Fullerton, California
- Hoag Family Cancer Institute - Hoag Memorial Hospital — Newport Beach, California
- Sutter Institute for Medical Research — Sacramento, California
Phase 3 Recruiting Industry
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Sponsor: Daiichi Sankyo
NCT ID: NCT06203210
Sites in California: - Clinical Research Providence Medical Foundation — Fullerton, California
- UCLA Hematology-Oncology — Los Angeles, California
- UCSF Mission Bay Mission Hall — San Francisco, California
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in California: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building — Irvine, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
Phase 3 Recruiting Industry
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in California: - ClinRé 001-022 (Premier Cancer Care and Infusion Center) — Fresno, California
- OPN Healthcare, Inc. — Glendale, California
- University of California Irvine — Orange, California
- Sutter Health — Roseville, California
- University of California San Francisco — San Francisco, California
Phase 3 Recruiting Industry
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in California: - Orange Coast Memorial Medical Center Fountain Valley — Fountain Valley, California
- California Research Institute — Los Angeles, California
- Los Angeles Cancer Network (LACN) — Los Angeles, California
- Providence Medical Foundation — Santa Rosa, California
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in California: - Hoag Hospital Newport Beach — Newport Beach, California
- University of California, Irvine Health — Orange, California
Phase 3 Recruiting Industry
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in California: - Chan Soon-Shiong Institute for Medicine — El Segundo, California
- MemorialCare - Orange Coast Medical Center — Fountain Valley, California
- OPN Healthcare INC — Glendale, California
- OPN Healthcare INC/ Cancer and Blood Specialty Clinic — Los Alamitos, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in California: - Hoag Memorial Hospital Presbyterian — Newport Beach, California